Description
NM-2201
NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that has similar properties to it’s close relatives 5F-PB-22 and NNE1, that are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.
NM-2201 can only be ordered if you are over 18 years of age.
Please ensure that NM-2201 is NOT controlled in the country/state to which you wish it to be delivered.
NM-2201 is not for human consumption.
Healthplus Research Chemicals are European based company specializing in retails and wholesale distribution of the best Re-find Research Chemicals.
Since our founding, we have been developing a vast catalog of products to meet the needs of our customers. We have grown our capabilities to include active pharmaceutical ingredient manufacturing, forensic analytical standard production, contract research service expertise, pre-clinical drug development, research grant support, and community outreach. Through all these endeavors, we remain committed to our origins and our founding vision: to provide affordable, high-quality products and to serve the research community.
Healthplus Research Chemicals is the best research chemicals shop to stock up on advanced materials for your experiments. You need someone you can trust when it comes to delivering 100% legitimate, absolutely pure chemicals and with us you can be absolutely certain in this regard. Our dedication to quality and scientific integrity has made us one of the most respected suppliers in the online market, a reputation we take very seriously and work hard to maintain. Healthplus Research Chemicals is regarded as the leader in international & offshore chemical supplier, chemical advisory terms with global range. Finest Research Chemical as a truly global supplier operates across 6 continents. We are known for our local and international market knowledge, expertise and experience balanced by an international reputation for the highest quality of service. Every new product or market trend is confirmed .
